Publication:
OMA1 protects from liver injury and tumorigenesis during aging by controlling hepatic immunogenicity.

dc.contributor.authorMartí-Mateos, Yolanda
dc.contributor.authorMuñoz-Hernández, María Del Mar
dc.contributor.authorGómez de Las Heras, Manuel M
dc.contributor.authorEscrig-Larena, José Ignacio
dc.contributor.authorCabrera-Alarcón, José Luis
dc.contributor.authorAcín-Pérez, Rebeca
dc.contributor.authorCalvo, Enrique
dc.contributor.authorJaroszewicz, Sara Natalia
dc.contributor.authorde Prado-Rivas, Lucía
dc.contributor.authorMartínez-Jiménez, Eva Raquel
dc.contributor.authorDe Andrés-Laguillo, Macarena
dc.contributor.authorGarcía-Domínguez, Esther
dc.contributor.authorGómez-Cabrera, María Carmen
dc.contributor.authorViña, José
dc.contributor.authorBenedito, Rui
dc.contributor.authorEfeyan, Alejo
dc.contributor.authorVázquez, Jesús
dc.contributor.authorMittelbrunn, María
dc.contributor.authorJiménez-Gómez, María Concepción
dc.contributor.authorEnríquez, José Antonio
dc.date.accessioned2026-07-16T12:12:24Z
dc.date.available2026-07-16T12:12:24Z
dc.date.issued2026-06-23
dc.description.abstractHepatic inflammation and immunosurveillance play major roles in the progression of liver cancer. A common trigger for hepatic inflammation is oxidative stress, which stems from mitochondrial dysfunction. Here, we demonstrate that deletion of the mitochondrial stress integrator OMA1 increases hepatic primary tumor incidence and impairs survival in mice. Persistent activation of the KEAP1-Nrf2 oxidative stress pathway in the absence of OMA1 promotes early liver injury, which progresses into chronic hepatic inflammation and fibrosis during aging. Exhausted CD8 and CD4 T cells gradually accumulate in Oma1 livers, facilitating hepatic tumor progression. Adoptive transfer and bone marrow-transplant experiments indicate that hepatic immunogenicity increases in the absence of parenchymal OMA1. Furthermore, hepatocyte-specific Oma1 deletion is sufficient to trigger NRF2 signaling, hepatocyte death, and immune exhaustion, suggesting that immunosurveillance during liver aging relies on the hepatic expression of OMA1. Given the therapeutic interest of OMA1 in several pathologies, these data are crucial to guide the generation of safe OMA1-targeted therapies.
dc.description.peerreviewed
dc.description.tableofcontentsWe are grateful to the Genoxphos Lab for stimulating discussion along these years and Drs. Marc Liesa and Estela Area-Gomez for their precious insights on the project. We would like to thank Prof. Thomas Langer for kindly providing the Oma1fl/fl mice; Antonio de Molina Iracheta and the CNIC Histopathology Unit for their invaluable guidance on liver histopathology; Marta Garcia Camacho and the CNIC Animal Physiology Unit for their technical support in analyzing plasma samples; and Olga Gimenez Saez and Veronica Labrador Cantarero for their help in designing Fiji macros for histological image analysis. J.A.E. is supported by the European Research Council grant ERC-2024-ADG (GA 101198761); by the PID2024-158440OB-100, TED2024-158440OB-I00, and PID2021-1279880B-100 funded by MCIN/AEI/10.13039/501100011033 and the European Union "NextGenerationEU"/Plan de Recuperacion Transformacion y Resiliencia/PRTR; by the CIBERFES (CB16/10/00282) & by the Fundacion "la Caixa" (LCF/PR/HR23/52430010). MM is supported by the European Research Council grant ERC-2021-CoG-101044248-Let T Be & by the Y2020/BIO-6350 NutriSION-CM synergy grant from Comunidad de Madrid. YMM was supported by the Ministerio de Ciencia, Innovacion y Universidades FPI Fellowship (PRE2018-083478). MMGH was supported by the Ministerio de Ciencia, Innovacion y Universidades FPU grant (FPU19/02576). JIE-L was supported by the Ministerio de Ciencia, Innovacion y Universidades (Spain). FPU grant FPU20/04066). Microscopy was conducted at the Microscopy & Dynamic Imaging, CNIC, ICTS-ReDib, co-funded by MCIN/AEI/10.13039/501100011033. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia, Innovacion y Universidades (MICIU), and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIU/AEI/10.13039/501100011033).
dc.identifier.citationEMBO J. 2026 Jun 23.
dc.identifier.journalEMBO JOURNAL
dc.identifier.pubmedID42332198
dc.identifier.urihttps://hdl.handle.net/20.500.12105/27602
dc.language.isoeng
dc.publisherSPRINGERNATURE
dc.relation.isreferencedbyPubMed
dc.relation.publisherversion10.1038/s44318-026-00839-4
dc.repisalud.institucionCNIC
dc.repisalud.orgCNICCNIC::Grupos de investigación::Proteómica cardiovascular
dc.rights.accessRightsopen access
dc.titleOMA1 protects from liver injury and tumorigenesis during aging by controlling hepatic immunogenicity.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
OMA1 protects from liver injury and tumorigenesis_EMBO J_2026.pdf
Size:
13.44 MB
Format:
Adobe Portable Document Format